Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
暂无分享,去创建一个
Masahiro Fukuoka | Yutaka Nishiwaki | Danny Rischin | Kazuhiko Nakagawa | Richard Eek | Jean-Yves Douillard | Johan Vansteenkiste | Takeshi Horai | G. Giaccone | E. Smit | Y. Nishiwaki | M. Fukuoka | J. Vansteenkiste | S. Kudoh | J. Douillard | S. Yano | D. Rischin | T. Tamura | K. Nakagawa | S. Averbuch | J. Baselga | Giuseppe Giaccone | I. Takata | Seiji Yano | A. Feyereislova | K. Noda | Tomohide Tamura | Kazumasa Noda | R. Eek | T. Horai | A. Macleod | R. Dong | Andrea Feyereislova | Shinzoh Kudoh | Ichiro Takata | Egbert Smit | Steven Averbuch | Angela Macleod | Rui-Ping Dong | José Baselga
[1] K. Pavelić,et al. Evidence for a role of EGF receptor in the progression of human lung carcinoma. , 1993, Anticancer research.
[2] M. Kris,et al. Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens , 2000 .
[3] N. Normanno,et al. Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.
[4] S. Pocock,et al. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.
[5] F. Fossella,et al. Management strategies for recurrent non-small cell lung cancer. , 1997, Seminars in oncology.
[6] Stephanie Green,et al. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria , 1992, Investigational New Drugs.
[7] D. Tulsky,et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. , 1995, Lung cancer.
[8] M. Kris,et al. Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: A review of two phase III trials. , 2001, Seminars in oncology.
[9] M. Paesmans,et al. Response to chemotherapy, quality of life benefits and survival in advanced non-small cell lung cancer: review of literature results. , 2001, Lung cancer.
[10] J. Schiller,et al. Current Standards of Care in Small-Cell and Non-Small-Cell Lung Cancer , 2001, Oncology.
[11] D. Lawrence,et al. Protein kinase inhibitors: the tyrosine-specific protein kinases. , 1998, Pharmacology & therapeutics.
[12] E. Dmitrovsky,et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] M. Kris,et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] E. Dmitrovsky,et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. , 1993, Cancer research.
[15] M. Volm,et al. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. , 1998, British Journal of Cancer.
[16] G. Giaccone,et al. Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] M. Kris,et al. Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR) , 2000 .
[18] J. Dancey,et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] H. Kato,et al. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. , 1996, European journal of cancer.
[20] D. Cella,et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. , 2002, Journal of clinical epidemiology.